All In Biotech

Drug Trial Radar · NCT00185159

Olmesartan Medoxomil in Diabetes Mellitus

Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)

Last checked: Nov 20, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,449

Actual

Start

Oct 2004

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Sankyo Pharma GmbhIndustry
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.

Conditions

  • Diabetes Mellitus, Type 2
  • Cardiovascular Disease
  • Kidney Disease

Interventions

  • Olmesartan medoxomilDrug

    tablets

  • Placebo TabletsDrug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urineTime frame: Time to the first occurrence

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Darmstadt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.